Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 4 publications
An Assessment of Time Toxicity in Patients Receiving [177Lu]Lu-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer (mCRPC).
Journal: The oncologist
Published: June 18, 2026
LuRa: Efficacy and Safety of Radium-223 Following [177Lu]Lu-PSMA-617 in Patients With Metastatic Castration-Resistant Prostate Cancer.
Journal: Clinical genitourinary cancer
Published: December 12, 2025
Evolution of Potentially Actionable Genomic Alterations in Advanced Prostate Cancer: A Real-World Analysis of Serial Circulating Tumor DNA Testing.
Journal: Cancers
Published: August 21, 2025
Outcomes for [177Lu]Lu-PSMA-617 with and Without Concurrent Use of Androgen Receptor Pathway Inhibitors in Patients with Metastatic Castration-resistant Prostate Cancer.
Journal: European urology oncology
Published: March 12, 2025
Showing 1-4 of 4
Last Updated: 09/26/2026